Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Trevi Therapeutics (NASDAQ:TRVI) and maintained an $8 price target on the stock.
May 08, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger reiterates a Buy rating on Trevi Therapeutics with an $8 price target.
The reiteration of a Buy rating and maintenance of an $8 price target by a reputable analyst like Serge Belanger from Needham is likely to instill confidence among investors and could positively influence Trevi Therapeutics' stock price in the short term. Analyst ratings, especially from well-regarded financial institutions, can significantly impact investor sentiment and stock prices.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100